€9.8m market cap
€0.21 last close
Hybrigenics is a French biotech company. It is developing its lead drug, inecalcitol, against orphan adult leukaemias and is currently conducting an international Phase II study in acute myeloid leukaemia. The company has a research programme on USP inhibitors and an R&D collaboration with Servier focused on USP inhibitors in oncology.
Investment summary
Edison Investment Research is terminating coverage on Hybrigenics (ALHYG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 2.6 | (3.5) | (4.0) | (11.2) | N/A | N/A |
| 2017A | 1.9 | (6.8) | (7.3) | (17.7) | N/A | N/A |
| 2018E | 3.6 | (3.5) | (4.1) | (8.7) | N/A | N/A |
| 2019E | 2.2 | (3.3) | (4.0) | (7.6) | N/A | N/A |
| Last updated on 14/01/2019 | ||||||
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (€m) | 1.5 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Alain Muňoz | Chairman |
| Rémi Delansorne | CEO |
| Guillaume Floch | CFO |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- Mologen
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma